Organon & Co. Declares Quarterly Dividend of $0.28 (NYSE:OGN)

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Thursday, May 2nd, Zacks reports. Shareholders of record on Monday, May 13th will be given a dividend of 0.28 per share on Thursday, June 13th. This represents a $1.12 annualized dividend and a yield of 5.71%. The ex-dividend date is Friday, May 10th.

Organon & Co. Stock Up 0.6 %

Shares of NYSE:OGN opened at $19.61 on Friday. The company has a market capitalization of $5.04 billion, a P/E ratio of 4.79, a P/E/G ratio of 0.92 and a beta of 0.81. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $24.08. The stock’s fifty day simple moving average is $18.17 and its 200-day simple moving average is $15.75.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.14. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 16.50% and a negative return on equity of 259.73%. On average, sell-side analysts anticipate that Organon & Co. will post 4.1 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Kirke Weaver acquired 2,720 shares of the stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $18.36 per share, with a total value of $49,939.20. Following the purchase, the insider now directly owns 15,181 shares of the company’s stock, valued at $278,723.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.17% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on OGN. The Goldman Sachs Group upped their price objective on shares of Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday. Piper Sandler raised their price objective on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, April 29th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.